Loading clinical trials...
Loading clinical trials...
The main objective of the study is evaluation of the safety and tolerability of RPESC-RPE-4W as therapy for dry AMD.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Luxa Biotechnology, LLC
Collaborators
NCT06557460 · Dry Age-related Macular Degeneration, Geographic Atrophy
NCT06165068 · Dry Age-related Macular Degeneration
NCT05797896 · Dry Age-related Macular Degeneration, Geographic Atrophy, and more
NCT07424235 · Age Related Macular Degeneration (AMD), Age Related Macular Degeneration, and more
NCT03846193 · Dry Age-related Macular Degeneration, Macular Degeneration, and more
Retina Vitreous Associates Medical Group
Beverly Hills, California
Spencer Center for Vision Research
Palo Alto, California
University of Michigan Kellogg Eye Center
Ann Arbor, Michigan
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions